Philogen (PHIL) H1 2024 earnings summary

Executive summary

• Announced a global commercialization agreement with Sun Pharma for Nidlegy and Fibromun, expanding previous regional deals and covering all indications worldwide, with a 45/55 post-commercialization economic split.

• Pipeline progress includes promising clinical results for Nidlegy in melanoma and non-melanoma skin cancers, and for Fibromun in soft tissue sarcoma and glioblastoma, both in late-stage clinical development.

• Chemistry pipeline advances highlighted, especially with the OncoACP3 ligand for prostate cancer, showing superior targeting and imaging compared to current PSMA ligands.

• Philogen operates two GMP-certified facilities in Siena and a research center in Zurich, supporting clinical and commercial production.

• The group is transitioning from a research-focused to a product-focused company, revising management structure and executive roles.

Financial highlights

• First half 2024 revenues were €1.7 million, down over 90% year-over-year, mainly due to the absence of milestone payments and lack of marketed products.

• Operating expenses rose to €16.9 million, reflecting accelerated clinical trials, manufacturing expansion, and workforce growth.

• EBITDA and net results showed a loss of about €15.5 million for the first half.

• Liquidity at end of June was €64.6 million, with a positive net cash position of €50.7 million after lease allocations.

• Philogen's stock rose 10.27% in H1 2024, outperforming sector indices, with a market cap of €828 million as of June 30, 2024.

Outlook and guidance

• EMA review of Nidlegy for melanoma expected to complete by mid-2025, with the first round of questions scheduled for October 2024.

• U.S. Phase III trial for Nidlegy ongoing with 104/186 patients enrolled; global registrational studies for non-melanoma skin cancers planned for early 2025.

• Anticipated readouts for Fibromun trials in soft tissue sarcoma and glioblastoma between December 2024 and April 2025.

• Management expects financials to be very positive by year-end, driven by new deals and ongoing activities.

• Plans to launch two pivotal Phase III trials for Nidlegy in 3rd line LaBCC and 2nd line LacSCC, each with fewer than 100 patients.